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Background: A new lung adenocarcinoma classification proposed by the International Association for the Study of
Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been
published. This study aimed to investigate the utility of the new histological classification for identifying the
prognostic subtypes of adenocarcinomas in stage IB patients.Correlations between the classification and the
presence of epidermal growth factor receptor (EGFR) mutation status was also studied.
Methods: One hundred and thirty-six patients with stage IB lung adenocarcinoma operated on in Zhejiang Cancer
Hospital were identified between 2002 and 2011. Patients overall survival and disease-free survival were calculated
using Kaplan-Meier and Cox regression analyses. EGFR mutations were detected using the amplification refractory
mutation system.
Results: A total of 136 cases were included in current study, of which 38 were papillary predominant, 39 were
acinar predominant, 22 were micropapillary predominant, 21 were lepidic predominant subtypes, 14 were solid
predominant, and 2 were variants of invasive adenocarcinoma. Patients with micropapillary- and solid-predominant
tumors had the lowest five-year disease-free survival (28.4 and 36.7%, respectively). Univariate and multivariate
analysis showed that the micropapillary-predominant subtype was an independent predictor of disease-free survival
(P = 0.0041 and 0.048, respectively), but not overall survival (P = 0.175 and 0.214, respectively). EGFR mutations were
significantly associated with the micropapillary-predominant subtype patients (P = 0.0026). The EGFR mutation
frequency is lower in the solid-predominant subtype than other subtypes (P = 0.0508).
Conclusions: The predominant subtype in the primary tumor was associated with prognosis in resected stage IB
lung adenocarcinoma. The EGFR mutation frequency of micropapillary-predominant subtype is higher than other
subtypes.
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Lung cancer is theleading cause of death in cancer pa-
tients worldwide [1]. The incidences of stage I non-small
cell lung cancer (NSCLC) has increased recent years.
However, recurrence and metastasis is a great challenge
in these patients. The five-year survival rates of patients
with resected stage I NSCLC is about 60% [2]. There is
a great need to predict which patients will recur in order
to develop strategies for choosing which patients
may benefit by adjuvant treatment. According to the
2013 National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology for NSCLC, stage
pathologic tumor node metastasis (pTNM) IB (tumor
size more than 3 cm and less than 5 cm or pleural
involvement) patients with complete resection are
treated with observation except for the patients with
high risk factors such as lymphatic and/or vessel inva-
sion, pleural involvement, and a tumor size of more than
4 cm. However, there is some dispute in this setting.
A new lung adenocarcinoma classification proposed by
the International Association for the Study of Lung Can-
cer, American Thoracic Society, and European Respira-
tory Society (IASLC/ATS/ERS) has recently been
published [3]. Many researchers have attempted to im-
plement a more meaningful pathological classification
which could provide prognostic and molecular biology
information with relevance to clinical behavior [4-7].
Epidermal growth factor receptor (EGFR) mutations
have been recently discovered and EGFR- -tyrosine kin-
ase inhibitor (TKI treatment has been played an import-
ant role in treating advanced NSCLC, especially for
EGFR mutation patients [8-10]. The frequency of EGFR
mutation has proven to be more common in adenocar-
cinoma [11]. However, the relationship between the
EGFR mutation and the subtype of the new lung adeno-
carcinoma classification is not clear.
This study reviewed a series of consecutive patients
with stage IB NSCLC who had been operated on in a
single institution according to the new IASLC/ATS/ERS
classification.It tracked the relationship between the pre-
dominant subtype of adenocarcinoma and prognosis, in
addition to detecting the Correlation between the new
subtype ofadenocarcinoma and EGFR mutations.
Methods
Patient eligibility
A total of 136 adenocarcinoma patients with pathologic
stage IB NSCLC, who underwent complete resection
between January 2002 and December 2011, were identi-
fied in Zhejiang Cancer Hospital. The Ethics Committee
at Zhejiang Cancer Hospital approved the study. All
patients underwent complete resection of lung cancer.
Histological typing was determined as adenocarcinoma
according to the 2004 World Health Organizationclassification. Lung cancer staging was performed for all
patients according to the seventh tumor node metasta-
sis (TNM) staging classification. All of the patients did
not receive preoperative chemotherapy or radiation
therapy.
Table 2 Univariate analysis of patient survival according to clinicopathologic characteristics
5-year DFS rate (%) P 5-year OS rate (%) P
Gender 0.313 0.601
Male (n = 79) 53.4 60.7
Female (n = 57) 51.7 66.7
Age (years) 0.643 0.475
<65 (n = 95) 50.1 59.7
≥65 (n = 41) 56.8 67.2
Smoking status 0.541 0.312
Never (n = 103) 56.5 70.6
Former or current (n = 33) 46.5 54.5
Tumor size 0.214 0.295
>3 cm (n = 89) 46.7 59.7
≤3 cm (n = 43) 54.2 66.2
Adjuvant chemotherapy 0.213 0.713
Yes (n = 37) 59.1 67.9
No (n = 99) 49.0 60.3
Grade 0.675 0.233
Well (n = 57) 59.6 73.3
Moderate or poor (n = 79) 50.1 55.4
Pleural involvement 0.769 0.961
Yes (n = 69) 49.0 60.4
No (n = 67) 55.2 67.5
Lymphatic and/or vessel invasion 0.045 0.112
Yes (n = 12) 39.1 51.7
No (n = 124) 54.3 68.1
Histological subtypes (IASLC/ATS/ERS)
Lepidicpredominant 0.042 0.307
Yes (n = 21) 75.2 80.8
No (n = 115) 50.8 59.3
Acinarpredominant 0.782 0.443
Yes (n = 39) 55..5 67.8
No (n = 97) 49.0 58.9
Papillary predominant 0.401 0.405
Yes (n = 38) 57.6 72.1
No (n = 98) 47.1 57.2
Micropapillary predominant 0.041 0.175
Yes (n = 22) 28.4 43.5
No (n = 114) 61.1. 62.9
Solid predominant 0.049 0.211
Yes (n = 14) 36.7 45.9
No (n = 122) 57.7 65.1
Variants of invasive adenocarcinoma 0.315 0.306
Yes (n = 2) 100 100
No (n = 134) 51.3 60.5
DFS, disease-free survival rate; OS, overall survival rate.
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Figure 1 Probability of disease-free survival and overall survival between lepidic-and solid-predominant subtype. A Probability of
disease-free survival comparison between lepidic-and solid-predominant subtype (P = 0.014). B Probability of overall survival comparison between
lepidic- and solid-predominant subtype (P = 0.031).
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All resected specimens were formalin fixed and stained with
hematoxylin and eosin in the routine manner. Each of the
slides was examined independently by three specialists. The
average number of slides from each case reviewed in our study
was 11.5 (range: 1 to 35). Histological classification was
according to the IASLC/ATS/ERS classification of lung adeno-
carcinoma and the 2004 WHO classification. According
to the IASLC/ATS/ERS criteria, each tumor was reviewed
using comprehensive histologic subtyping, recording thepercentage in 5% increments for each histologic component.
Tumors were classified as adenocarcinomas in situ (AIS),
minimally invasive adenocarcinomas (MIA), and invasive
adenocarcinomas. Adenocarcinomas were further subdivided
into lepidicpredominant (Lepidic), papillarypredominant
(Pap), acinarpredominant (Aci), micropapillarypredominant
(MP), solidpredominant (Solid), invasive mucinous adenocar-
cinoma and others (including colloid adenocarcinoma and
fetal adenocarcinoma). The predominant pattern is defined as
the pattern with the largest percentage.
Figure 2 Probability of disease-free survival and overall survival between lepidic- and micropapillary-predominant subtype. A
Probability of disease-free survival comparison between lepidic- and micropapillary-predominant subtype (P = 0.001). B Probability of overall
survival comparison between lepidic- and micropapillary-predominant subtype (P = 0.021).
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Molecular analysis of EGFR was performed using the
amplification refractory mutation system (ARMS) with
formalin-fixed paraffin embedded archival tissue blocks
obtained during surgical excision of the tumors. The
examination method followed was that of Lynch et al.
[12].
Follow-up
Patients were examined at three-month intervals for the
first two years and at six-month intervals thereafter. The
follow-up evaluation included a physical examination, acomputed tomography scan of the chest and abdomen,
brain magnetic resonance imaging, and bone scintig-
raphy. The last follow-up date was 31 May 2013. The
median survival time from surgery to the last censoring
date was 74 months (range, 21 to 145 months).
Results
Clinicopathologic and histologic features
The clinicopathologic characteristics of the patients are
listed in Table 1. The median age of the patients was
57.6 years in the current cohort. Of the136 patients, 103
Figure 3 Probability of disease-free survival and overall survival between acinar- and papillary-predominant subtype. A Probability of
disease-free survival comparison between acinar- and papillary-predominant subtype (P = 0.814). B Probability of overall survival comparison be-
tween acinar- and papillary-predominant subtype (P = 0.761).
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current smokers.
Of the 136 invasive adenocarcinoma cases, 38 were
papillarypredominant, 39 were acinarpredominant, 22
were micropapillarypredominant, 14 were solidpredomi-
nant, 21 were lepidicpredominant subtypes, and 2 were
variants of invasive adenocarcinoma (Table 1). A total of
12 specimens showed a single pattern, whereas 32 dis-
played two, 54 displayed three, and 40 displayed at least
four patterns. Two patients were variants of invasive
adenocarcinoma (colloid adenocarcinoma).Survival analyses
Table 2 shows the results of the univariate analyses of
the clinicopathologic and histologic factors evaluated in
this study. The five-year disease-free survival rate (DFS)
and overall survival rate (OS) for the all patients were
52.4 and 62.0%, respectively. Lymphatic and/or vessel in-
vasion, micropapillary-predominant subtype, and solid-
predominant subtype correlated significantly with a
worse DFS (P = 0.045, P = 0.041, and P = 0.049, respect-
ively), although these were not significantly different for
OS. There was a significant difference between different
Table 3 Multivariate survival analysis for disease-free survival and overall survival
DFS OS
HR 95% CI P HR 95% CI P
Lepidic predominant (yes/no) 0.756 0.723-1.012 0.101 0.876 0.597-1.986 0.742
Micropapillary predominant (yes/no) 1.473 1.041-1.786 0.048 1.342 0.764-1.987 0.214
Solid predominant (yes/no) 1.210 0.987-1.978 0.076 1.229 0.746-2.158 0.435
lymphatic and/or vessel invasion (yes/no) 1.153 0.979-2.143 0.079 1.075 0.774-3.547 0.843
DFS, disease-free survival; OS, overall survival.
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and 3).
A multivariate Cox’s regression model was constructed
considering lymphatic and/or vessel invasion, micropa-
pillary predominant, solid predominant, and lepidic
predominant as variables. Micropapillary predominant
qualified as an independent prognostic factor for DFS
but not OS (Table 3).
Correlation with EGFR mutation and clinicopathologic
characteristics
A total of 102 out of 136 patients provided tumor samples
for EGFR mutation analysis. EGFR mutations were identi-
fied in 39 (38.2%) patients (22 with exon 19 delete and 17
with exon 21 L858R mutation). There was a significant
difference among the patients with EGFR mutation fre-
quency between the micropapillary-predominant subtype
and other subtypes (P = 0.0026). In contrast, EGFR muta-


















Variants of invasive adenocarcinoma
Yes 0 (0.0%)
No 39 (100%)than in the other subtypes (P = 0.0508) (Table 4). There
was no significant difference between other subtypes and
EGFR mutations.
Discussion
In the presented study, the data indicated that the
IASLC/ATS/ERS histologic subtypes of lung adenocar-
cinoma could predict the prognosis of stage IB patients.
EGFR-mutated tumors were more likely to be of the
micropapillary-predominant subtype and were less fre-
quent in the solid-predominant subtype. The prognostic
impact of the new classification on recurrence has been
validated in several studies [13,14]. Yoshizawa et al. [7]
reported that the IASLC/ATS/ERS histologic classifica-
tion was predictive of prognosis in stage I adenocarcin-
oma. Their data revealed that AIS and MIA had a
100.0% five-year DFS. Lepidic predominant, papillary
predominant, and acinar-predominant subtypes had a
90.0%, 83.0%, and 84.0% five-year DFS, respectively. Inn with epidermal growth factor receptor mutation (EGFR)
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adenocarcinomas had a lower risk of recurrence,
whereas micropapillary- and solid-predominant adeno-
carcinomas had a higher risk for recurrence. In our
study, the lepidic-predominant adenocarcinomas were
shown to have a better prognosis compared with other
subtypes.The micropapillary- and solid-predominant
adenocarcinomas had the worst prognosis, which is
similar to the results from the Hung et al. study [14].
The prognostic value of the new classification on OS
has also been researched in several studies [4-7,13,14].
Micropapillary- and solid-predominant adenocarcinomas
showed poor OSwhen compared with other subtypes in
the Song et al. study [15]. However, no survival differ-
ence for post-recurrence was identified among different
subtypes in the Hung et al. cohort study [14]. In our co-
hort study, no difference was found in thefive-year OS
between different histology subtypes in univariate and
multivariate analyses, which may due to the different
treatment after recurrence or metastases, such as EGFR-
TKI therapy.
The relationship between EGFR mutations and pre-
dominant subtype has been examined in several studies
[16,17]. The data between the EGFR mutation and hist-
ology subtype are conflicting. Zhang et al. [17] investi-
gated 349 lung adenocarcinoma cases and found EGFR
mutations were more frequent in acinar-predominant
tumors. However, EGFR mutations were found to be
more frequent in micropapillary-predominant tumors in
the Shim et al. and Song et al. studies [16,18]. Our re-
sults showed that EGFR mutations was more frequent in
micropapillary-predominant subtypes (P = 0.0026). The
different outcome between EGFR mutations and hist-
ology subtypes may be related to study sample size and
ethnic difference.
Our study’s major limitations were being retrospective
and from a single institution. In addition, EGFR muta-
tion data was not available for all of the patients, thereby
limiting the inferences possible from our clinical study.
However, with the small number of patients in clinical
trials, our retrospective study is still meaningful.Conclusions
In conclusion, we have demonstrated the prognostic
value of the new classification in stage IB lung adenocar-
cinoma patients. This new classification might be valu-
able for detecting patients with a high risk of recurrence
in order for them to receive postoperative adjuvant
treatment. EGFR mutations were found more frequently
in micropapillary-predominant tumors in this study.
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